- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 29.04. | OKYO Pharma LTD: OKYO CEO and CSO to Present and Leadership Team to Participate at Upcoming Scientific Conferences in May | 345 | GlobeNewswire (Europe) | Robert J. Dempsey, MBA, Chief Executive Officer, to present at EyeceleratorRaj Patil, PhD, Chief Scientific Officer, to present at ARVO
LONDON and NEW YORK, April 29, 2026 (GLOBE NEWSWIRE) -- OKYO... ► Artikel lesen | |
| OKYO PHARMA Aktie jetzt für 0€ handeln | |||||
| 29.04. | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 07.04. | OKYO Pharma beruft Expertengremium zu Medikamentenkandidat Urcosimod ein | 3 | Investing.com Deutsch | ||
| 07.04. | OKYO Pharma plant Expertentreffen zu Urcosimod auf ASCRS-Jahrestagung | 1 | Investing.com Deutsch | ||
| 07.04. | OKYO Pharma to hold advisory board meeting at ASCRS conference | 1 | Investing.com | ||
| 07.04. | OKYO Pharma Announces Scientific Advisory Board Meeting and Urcosimod Data Presentation During ASCRS Annual Meeting | 309 | GlobeNewswire (Europe) | LONDON and NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 07.04. | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 19.03. | OKYO Pharma Announces Chairman and Founder Acquires Shares | 360 | GlobeNewswire (Europe) | LONDON and NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 19.03. | OKYO Pharma Announces Director Acquires Shares | 415 | GlobeNewswire (Europe) | LONDON and NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 19.03. | OKYO Pharma Announces Chief Development Officer and Director Acquires Shares | 443 | GlobeNewswire (Europe) | LONDON and NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 18.03. | OKYO Pharma reports quality of life improvements in pain trial | 2 | Investing.com | ||
| 18.03. | OKYO Pharma Reports New Phase 2 Data Demonstrating Meaningful Improvements in Patient-Reported Quality of Life Outcomes with Urcosimod in Neuropathic Corneal Pain | 381 | GlobeNewswire (Europe) | LONDON and NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 12.03. | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 23.02. | OKYO Pharma LTD: OKYO Abstract Selected for Presentation at Premier Global Ophthalmology Congress | 311 | GlobeNewswire (Europe) | LONDON and NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 23.02. | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 20.02. | Piper Sandler startet Coverage für OKYO Pharma mit 'Overweight'-Rating | 3 | Investing.com Deutsch | ||
| 20.02. | Piper Sandler initiates OKYO Pharma stock with Overweight rating | 2 | Investing.com | ||
| 13.02. | OKYO Pharma kündigt Aktienplatzierung im Wert von 20 Millionen US-Dollar an | 1 | Investing.com Deutsch | ||
| 13.02. | OKYO Pharma prices public offering at $1.85/share to raise up to $20M | 3 | Seeking Alpha | ||
| 13.02. | OKYO Pharma Announces Pricing of $20 Million Public Offering of Ordinary Shares | 493 | GlobeNewswire (Europe) | LONDON and NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen |
1 2 3 4 Weiter >>
71 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| IDEXX LABORATORIES | 452,10 | -0,64 % | BofA Sees Slower InVue Installations as Headwind for IDEXX Laboratories, Inc. (IDXX) | ||
| BIOXCEL THERAPEUTICS | 1,025 | +0,99 % | BioXcel Therapeutics Announces Enrollment of First Patients in U.S. Department of War-Funded Study of BXCL501 (Sublingual Dexmedetomidine) for Treatment of Acute Stress Reactions | DoW-funded Phase 2a trial led by University of North Carolina at Chapel Hill (UNC) Institute for Trauma Recovery Positive outcomes from trial can potentially impact Veteran Affairs/Department of... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 3,766 | +6,69 % | Voyager Therapeutics, Inc.: Voyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer's Disease Expected H2 2026 | - VY1706 IND application process on track for Q2 2026; clinical entry expected H2 2026 - - Data from eight ASGCT presentations highlight Voyager's continued innovation in gene therapy - LEXINGTON... ► Artikel lesen | |
| ADAPTIMMUNE THERAPEUTICS | 0,016 | +128,57 % | Adaptimmune Therapeutics PLC: Adaptimmune Announces Changes to Board and Executive Leadership Team | Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 17, 2025) - Adaptimmune Therapeutics plc (OTC Pink: ADAPY) ("Adaptimmune" or the "Company") today announced changes... ► Artikel lesen | |
| ANAVEX LIFE SCIENCES | 2,600 | -0,08 % | ANAVEX LIFE SCIENCES CORP in stabiler Marktphase | ||
| PRECISION BIOSCIENCES | 7,140 | +2,15 % | Precision BioSciences, Inc.: Precision BioSciences Announces Late-Breaking Poster Presentation for PBGENE-HBV at European Association for the Study of the Liver Congress 2026 | Late-breaking poster presentation to highlight new biopsy data demonstrating elimination and inactivation of cccDNA from the ongoing Phase 1 ELIMINATE-B trial in chronic hepatitis B
Precision... ► Artikel lesen | |
| CELLAVISION | 10,640 | -3,27 % | Dividendenbekanntmachungen (29.04.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) 2020 BULKERS LTD BMG9156K1018 258,95 NOK 23,7146 EUR ACROW LIMITED AU0000006124 0,02 AUD 0,0122 EUR ADVENICA AB SE0006219473 0... ► Artikel lesen | |
| ZYMEWORKS | 20,900 | +3,11 % | N-Zyme Biomedical Inc.: N-Zyme Biomedical Applauds FDA's Newly Announced Initiatives Supporting Drug Repurposing for Unmet Medical Needs | Clinical-stage biotechnology company supports efforts to advance therapies addressing significant unmet clinical needs NEWARK, DE / ACCESS Newswire / May 13, 2026 / N-Zyme Biomedical, a clinical-stage... ► Artikel lesen | |
| VTV THERAPEUTICS | 26,800 | +6,35 % | vTv Therapeutics Inc.: vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | ||
| QUOIN PHARMACEUTICALS | 4,800 | -3,23 % | Quoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Provides Corporate Update and Reports First Quarter 2026 Financial Results | - Filed Breakthrough Medicine Designation Application with Saudi FDA for QRX003 in Netherton Syndrome - Submitted Application to Japanese MHLW for Orphan Drug Designation (ODD) for QRX003; MHLW... ► Artikel lesen | |
| NEUPHORIA THERAPEUTICS | 5,010 | +1,62 % | Neuphoria Therapeutics, Inc.: Neuphoria Provides Facts, Exposes False Narratives in Response to Lynx1 Fictions | BURLINGTON, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. ("Neuphoria" or the "Company") (NASDAQ: NEUP), a clinical-stage biotechnology company dedicated to developing therapies... ► Artikel lesen | |
| PLIANT THERAPEUTICS | 1,036 | +2,57 % | Pliant Therapeutics, Inc.: Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results | First participant dosed in FORTIFY, a Phase 1b indication expansion trial of PLN-101095Oral presentation at AACR 2026 featured updated data from Phase 1 trial of PLN-101095 showing deepening of confirmed... ► Artikel lesen | |
| MIRA PHARMACEUTICALS | 0,841 | -2,72 % | MIRA Pharmaceuticals Announces Acceptance of Peer-Reviewed SKNY-1 Manuscript Highlighting Oral Obesity and Nicotine Addiction Drug Candidate | Peer-reviewed publication highlights preclinical findings demonstrating weight loss, lipid normalization, and reduction of compulsive feeding and nicotine-seeking behaviors MIAMI, FL / ACCESS Newswire... ► Artikel lesen | |
| NUVATION BIO | 4,775 | -1,24 % | Nuvation Bio Inc.: Nuvation Bio Announces FDA Acceptance of Supplemental New Drug Application for IBTROZI (taletrectinib) with Updated Duration of Response in Advanced ROS1-Positive Non-Small Cell Lung Cancer | Application includes updated TRUST-I TKI-naïve median duration of response (mDOR) and median progression-free survival (mPFS) of more than 4 years, as well as TRUST-II... ► Artikel lesen | |
| ONCONETIX | 0,387 | -5,10 % | Onconetix, Inc.: Onconetix Reports Q1 2026 Progress at Proteomedix AG, Including Two New Peer-Reviewed Publications and Initiation of U.S. Validation Study | New Clinical Data Reinforce Proclarix® Performance in Reducing Overdiagnosis and Unnecessary Biopsies; Multi-Center PRIME Study Initiated in Collaboration with Labcorp; European Commercial Expansion... ► Artikel lesen |
OKYO PHARMA LIMITED gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 1,610 Euro und damit -0,62 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OKYO PHARMA LIMITED finden Sie auf Wallstreet Online.